Abstract

Prestige Consumer Healthcare will report results on August 06, 2026 Pre-Market; our preview synthesizes the company’s guidance, last quarter’s print, and current-quarter forecasts including revenue, margins, and EPS alongside prevailing analyst sentiment.

Market Forecast

Consensus tracking for the current quarter points to revenue of 249.68 million US dollars, an estimated year-over-year change of -4.34%, EBIT of 67.23 million US dollars with a -11.88% YoY change, and EPS of 0.88 with a -12.10% YoY change; company-level commentary and recent coverage suggest margin pressure will persist near term. The gross profit margin is expected to track in the low-50% range, with the last reported gross profit margin at 52.98%, and net profitability likely softer with EPS contraction implied; adjusted EPS is guided to decline on a YoY basis. Management and market color highlight stabilization in core over-the-counter categories while supply constraints and timing effects are key watch items for near-term performance. The most promising segment appears to be women’s health given category resilience, though absolute revenue leadership remains in gastrointestinal products; women’s health contributed 227.77 million US dollars last quarter, and investors will look for normalization from recent supply and mix headwinds.

Last Quarter Review

Prestige Consumer Healthcare’s prior quarter delivered revenue of 281.17 million US dollars, a gross profit margin of 52.98%, GAAP net profit attributable to shareholders of 53.93 million US dollars, a net profit margin of 19.15%, and adjusted EPS of 1.23, with revenue down 5.18% year over year and adjusted EPS down 6.82% year over year. A key highlight was quarter-on-quarter improvement in net profit, with the quarter-over-quarter growth rate at 15.49%, supported by operating expense control despite lower sales. Main business performance showed gastrointestinal products as the largest revenue contributor at 259.79 million US dollars, followed by women’s health at 227.77 million US dollars; investors remain attentive to SKU availability and channel inventory timing effects.

Current Quarter Outlook (with major analytical insights)

Core OTC portfolio and revenue trajectory

Prestige’s near-term revenue line is projected at 249.68 million US dollars, implying a 4.34% year-over-year decline. This follows a softer fiscal fourth quarter tied to constrained supply for Clear Eyes and pull-forward order timing in the preceding period. We expect organic growth to track in the low single-digit negative range this quarter as the company cycles through inventory normalization at retail and rebuilds service levels in eye and select seasonal categories. The portfolio’s breadth across gastrointestinal care, women’s health, dermatology, and pain relief helps mitigate category volatility, but the mix shift away from certain higher-velocity SKUs may weigh on top-line momentum. Promotional intensity in certain OTC aisles and retailer focus on working capital could also modestly dampen sell-in. Against this backdrop, watch for sequential improvement in order rates as shelf conditions normalize late in the quarter, which may set a more favorable base for the subsequent print.

Women’s health performance and medium-term catalysts

Women’s health remains a resilient pillar within the franchise, with last quarter revenue of 227.77 million US dollars across trailing twelve months within the category footprint. Although the current quarter forecast embeds a companywide revenue step-down, the women’s health assortment tends to benefit from steadier demand patterns and strong brand equities. Category elasticity should support stable volumes even amid selective pricing rollbacks or promotional calibrations designed to enhance shelf velocity. The principal medium-term drivers include ongoing consumer trade-up within personal care and potential cross-channel marketing synergies to increase household penetration. Any incremental innovation drops or distribution gains would disproportionately benefit this category as supply recovers. The key risk is retailer-level inventory discipline that delays replenishment for certain sub-lines until service-level metrics sustain above threshold, which could defer recognition into the following quarter.

Margins, EPS sensitivity, and what will move the stock

The forecast embeds EBIT of 67.23 million US dollars and EPS of 0.88, with implied year-over-year declines of 11.88% and 12.10%, respectively. Gross margin last quarter printed at 52.98% and is likely to remain in the low-50% area as input costs and idle-capacity remediation roll off gradually. The path to EPS stabilization hinges on reattaining normalized manufacturing throughput and smoothing remediation-related overhead absorption. On operating expenses, disciplined advertising and promotion phasing should protect profitability without compromising brand support, though any additional investment to reaccelerate volumes would weigh on the near-term run-rate. The stock is likely to be most sensitive to management’s qualitative color on supply chain normalization, updated fiscal-year revenue and adjusted EPS guardrails, and any visibility on the cadence of recovery in eye care. Confirmation that Clear Eyes and other affected SKUs are approaching historical service levels could prompt multiple relief, whereas evidence of prolonged under-supply would pressure both estimates and sentiment.

Analyst Opinions

Recent coverage during the period reflects a mixed but constructive skew in opinions on Prestige Consumer Healthcare. Negative sentiment followed the weak fiscal fourth-quarter performance and conservative new fiscal-year framework, including a downgrade to Perform from a major sell-side house after revenue fell 5% and adjusted EPS missed consensus. Offsetting these views, several analysts maintained Buy ratings, citing upside from recent brand acquisitions and an underappreciated earnings power once supply constraints fade. Notably, William Blair reiterated a Buy rating, emphasizing that integration and brand stewardship can unlock earnings leverage as remediation costs normalize. Canaccord Genuity also reaffirmed a Buy stance with an 86 US dollars target in its assessment of the Breathe Right acquisition’s accretive characteristics and category expansion potential. Overall, the ratio of bullish to bearish commentary leans positive, and the majority view expects a gradual improvement across the back half of the fiscal year as service levels recover and operating discipline supports margins. The dominant thesis argues that near-term softness is transitory, with valuation support anchored by durable cash generation and portfolio diversification that should enable Prestige Consumer Healthcare to reaccelerate EPS growth once supply friction abates.